1. Home
  2. PACS vs GKOS Comparison

PACS vs GKOS Comparison

Compare PACS & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PACS Group Inc.

PACS

PACS Group Inc.

N/A

Current Price

$34.49

Market Cap

6.5B

Sector

N/A

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$103.96

Market Cap

6.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PACS
GKOS
Founded
2013
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5B
6.9B
IPO Year
2024
2015

Fundamental Metrics

Financial Performance
Metric
PACS
GKOS
Price
$34.49
$103.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
14
Target Price
$45.50
$133.07
AVG Volume (30 Days)
922.1K
679.7K
Earning Date
05-25-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
221.05
N/A
EPS
1.22
N/A
Revenue
$5,288,932,000.00
$507,442,000.00
Revenue This Year
$10.04
$23.39
Revenue Next Year
$9.30
$27.46
P/E Ratio
$28.25
N/A
Revenue Growth
29.32
32.33
52 Week Low
$7.50
$73.16
52 Week High
$43.08
$130.23

Technical Indicators

Market Signals
Indicator
PACS
GKOS
Relative Strength Index (RSI) 41.17 35.28
Support Level $33.11 $81.54
Resistance Level $35.10 $106.52
Average True Range (ATR) 1.90 3.58
MACD -0.62 -1.81
Stochastic Oscillator 14.32 14.28

Price Performance

Historical Comparison
PACS
GKOS

About PACS PACS Group Inc.

PACS Group Inc is a post-acute healthcare company mainly focused on delivering high-quality skilled nursing care through a portfolio of independently operated facilities Its is a nursing providers in the United States based on number of facilities, with over 200 post-acute care facilities across nine states serving over 20,000 patients daily. It also provide senior care, assisted living, and independent living options in some of communities.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: